Acute brain injuries cause rapid cell death that activates bidirectional crosstalks between the injured brain and the immune system.
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Introduction
Although considered for many years an immune privileged tissue, it is today well accepted that the central nervous systems (CNS) is engaged in an intense bidirectional communication with the immune system. The CNS physiologically controls peripheral immunity through complex humoral signalling and via the direct activation of neuronal pathways that include the hypothalamic-pituitary-adrenal axis and the autonomic nervous system .
The hypothalamus normally suppresses the release of pro-inflammatory cytokines from T cells, monocytes and macrophages, while promoting the systemic release of antiinflammatory cytokines, such as interleukin (IL)-10 (Chamorro et al., 2012) . Similarly, the release of noradrenaline from the autonomic centres and peripheral organs (including the adrenal medulla, liver and spleen) induces a constitutive anti-inflammatory phenotype in circulating immune cells (Meisel et al., 2005) . The immune system is in turn responsible for CNS development, surveillance and response to damage. In the developing brain, a large percentage of the processes underlying neurogenesis and dynamic pruning (i.e. the selective degeneration of whole or parts of dendrites and axon collaterals) is mediated by resident immune cells (Besedovsky and Rey, 2007; Boulanger, 2009) . Later in adulthood, both resident and circulating immune cells function as primary guardians of the CNS and their sentinel duties contribute to the maintenance of normal homeostasis (Chamorro et al., 2012; Ousman and Kubes, 2012) . Immune mechanisms are indeed responsible for the constant remodelling of neural circuits, memory consolidation, hippocampal long-term potentiation and neurogenesis in response to everyday environmental stimuli (Meisel et al., 2005; Yirmiya and Goshen, 2011) .
After focal damage, the lesioned area undergoes acute loss of function and neurodegeneration, which are later followed by a regenerative response finalized at restoring both structures and functions. As the first line of defense in the CNS, the immune system provides the earliest responses against acute brain injury, consisting of both physical and chemical barriers created by innate immune cells (microglia/macrophages, neutrophils, and natural killer cells) and the complement system (Gelderblom et al., 2009) . In this acute phase immune cells actively participate in the disruption of the blood brain barrier (BBB), remodelling of the extracellular matrix (ECM), and activation of glial cells (reactive gliosis), while protecting neurons from increasing excitotoxicity, calcium release and free radicals (Dirnagl et al., 1999) . This first intense systemic immune activation orchestrates the clearance of necrotic debris and the containment of the initial damage (Kamel and Iadecola, 2012) .
The role of the immune system in the following regenerative phase within the CNS is however far from being fully elucidated. The CNS copes with injury and loss of function by enacting a variety of functional and structural changes in neural pathways and synapses, which are commonly referred to as CNS plasticity. In particular, a first phase of functional plasticity characterized by dendritic reorganization and axonal sprouting is followed by a second phase of structural neuroanatomical plasticity (generation of new neurons and vessels) ultimately leading to the formation of novel connections within the damaged brain (Wieloch and Nikolich, 2006) . The components of both the innate and adaptive (T and B lymphocytes) immune responses profoundly shape functional and structural plasticity of the injured CNS by priming (or hindering) brain recovery via modulation of intrinsic growth properties and extrinsic growth-regulatory cues (Martino et al., 2011) .
It is increasingly clear that many of the events that characterize the first acute neurodegeneration are linked (directly or indirectly) with the following regenerative phase, and that the immune activation within the CNS must be interpreted in a continuum between degenerative and reparative processes (Hermann and Chopp, 2012) . In this review we focus on the role exerted by the innate and the adaptive immune response in regulating CNS plasticity through the different phases of acute injury and subsequent recovery. In particular, we explore the ability of the immune system to modulate the initial BBB damage and glial activation, the following functional plasticity of neurons, and the final reparative regeneration of the injured CNS (Fig. 1) . Since most of currently available evidences related to the innate and adaptive immune responses after damage derive from CNS focal sterile injuries, we mainly focus on describing the pathophysiology and the evolution of acute (focal) damage after experimental ischemic stroke and spinal cord injury (SCI).
BBB damage and reactive gliosis
The BBB is made by endothelial cells, pericytes, astrocytes and ECM that, together with neurons, are organized in a complex cellular system called the neurovascular unit (NVU) (Abbott et al., 2006) . Upon ischemic brain injury, the NVU undergoes intense early changes that comprise failure of ion pumps, overaccumulation of intracellular sodium and calcium, loss of membrane integrity and necrotic cell death. Release of damage-associated molecular patterns (DAMPs) from necrotic cells activates pattern recognition receptors (PRRs) of the resident immune cells (microglia) that include Toll-like receptors (TLRs), RIG-1-like receptors (RLRs), NOD-like receptors (NLRs), AIM2-like receptors (ALRs) and C-type lectin receptors (Hanke and Kielian, 2011; Chamorro et al., 2012) . Activation of PRRs on microglial cells triggers downstream signalling pathways, such as the nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB), the mitogen-activated protein kinase (MAPK) and type 1 interferon (IFN) pathway, which in turn upregulate proinflammatory cytokines, chemokines, costimulatory signals and reactive oxygen species (ROS) (Takeuchi and Akira, 2010) . Infiltrating neutrophil granulocytes are the first circulating immune cells to appear within the ischemic lesion and they virtually overwhelm the ischemic hemisphere by 3 days postreperfusion (Gelderblom et al., 2009) . Upon infiltration, neutrophils start producing inducible nitric oxide synthase (iNOS), an enzyme that generates toxic amounts of nitric oxide (NO), and release both matrix metalloproteinases (MMPs) and myeloperoxidase (MPO) (Justicia et al., 2003) . Release of MMP-9, as well as the upregulation of MPO within the ischemic tissue, contribute to the further down-regulation of junctional proteins and are the main contributors to the first derangement of the BBB (Bao Dang et al., 2013; Peruzzotti-Jametti et al., 2013) .
Initial BBB disruption is soon enhanced by ECM degradation, which participates in the secondary ischemic brain damage by permitting serum elements to enter the perivascular space (Asahi et al., 2001; Elali et al., 2011) . Resident macrophages and mast cells (MCs) become further activated, leading to the release of vasoactive mediators and proinflammatory cytokines, which in turn recruit and promote the infiltration of more leukocytes. Activated mast cells (MCs) secrete MMP-2 and MMP-9 that further damage most of the protein constituents of the ECM (like collagen, elastin, fibronectin, vitronectin and gelatin), while MCs-derived tryptases and chymases cleave and activate fibronectin, procollagenases (Saarinen et al., 1994) , pro-MMP-2 and pro-MMP-9 (Tchougounova et al., 2005) . Likewise, eosinophils have a major role on enhancing BBB and ECM disruption after ischemic injury through the secretion of eosinophil derived MMPs and elastases (Jacobsen et al., 2007) . Once degraded, the ECM releases growth factors, such as the vascular endothelial growth factor (VEGF) and the transforming growth factor (TGF)-β, that are normally bound to the ECM in their zymogen form (Zlokovic, 2006) . Released growth factors, infiltrating immune cells and the accumulation of blood born soluble mediators within the perivascular space finally activate CNS astrocytes at the lesion border.
The role of these 'reactive astrocytes' has been extensively investigated in mouse models of spinal cord injury. Within areas of BBB damage, astrocytic activation mainly ensues after SCI as a direct consequence of the local inflammatory reaction (Burda and Sofroniew, 2014) . Activated macrophages and microglia start secreting leukaemia inhibitory factor (LIF) and IL-6, which promote astrocytic differentiation of progenitor cells (Nakanishi et al., 2007) . MCs attract astroglial processes to elongate in their close proximity (Khalil et al., 2007) and neutrophils induce early astroglial activation through the production of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, TGF-α, ROS, IL-1 and IL-6 (Silver and Miller, 2004) . This early immune-mediated activation of astrocytes is of pivotal importance for the NSC-14-308_R1 6 final outcome after SCI. As a matter of fact, the treatment of mice with anti-Ly6G/Gr-1 (an antibody that results in a profound loss of neutrophils) reduces the early astrocytic reactive gliosis, thus hampering neurological recovery and increaseing lesion area (Stirling et al., 2009 ).
Following acute CNS damage, activated astrocytes increase the expression of intermediate filament proteins, such as vimentin and glial fibrillary acidic protein (GFAP), and secrete chondroitin sulfate proteoglycans (CSPGs), such as neurocan, phosphacan and versican (Rhodes and Fawcett, 2004) . Reactive astrocytes and CSPGs form an insuperable barrier (the glial scar), which restricts extravasated leukocytes to perivascular clusters and thereby reduce further detrimental infiltration of immune cells into the adjacent CNS parenchyma. Besides their role in structural confinement, astrocytes can also directly repair the BBB (Alvarez et al., 2013) to prevent an overwhelming inflammatory response (Bush et al., 1999) . Interestingly, it has been recently shown that resident astrocytes and ependymal neural stem cells (NSC)-derived astrocytes, which both participate in spinal cord glial scar formation, have different functions. Resident astrocytes form the peripheral part of the scar, while ependymal NSC-derived astrocytes constitute its central part (Barnabé-Heider et al., 2010) . Moreover, while the former are implicated in restricting the infiltration of inflammatory cells (Okada et al., 2006; Herrmann et al., 2008) and in inhibiting the degranulation of neutrophils (Xie et al., 2010) , the latter is required to reinforce the injured spinal cord (Sabelström et al., 2013) .
Despite astroglial activation has major positive features in the initial response to damage (mainly by prompting early stabilization of injured tissue), the glial scar represents a major impediment for axonal regrowth and other regenerative mechanisms in the following phases (Silver and Miller, 2004) . A certain degree of astroglial modulation and ECM remodelling is therefore needed to initiate pro-regenerative adaptive responses within the damaged CNS (Zuo et al., 1998) . The role of the immune cells in this phase is once more fundamental. Mast cells can secrete mouse mast cell protease 4 (mMCP4), a chymase that is able to degrade inflammatory-associated cytokines and to reduce astrogliosis (Nelissen et al., 2014) , while eosinophils might amplify complement-dependent cell-mediated cytotoxicity (CDCC) on astrocytes (Boulanger, 2009; Zhang and Verkman, 2013) . Apoptotic neutrophils within the lesion border can affect nearby reactive microglia/macrophages by promoting a switch towards the alternative anti-inflammatory phenotype (M2) (Filardy et al., 2010) . Once polarized, M2-like macrophages start producing anti-inflammatory IL-10 and increase the expression of MMP-13, which allows the remodelling of the scar matrix into a more permissive environment for axonal re-growth (Shechter et al., 2011) . This polarization towards the IL-10 hi IL-12 low M2-like anti-inflammatory phenotype is also dependent on IL-6 secretion by astrocytes and on the direct interaction of CSPGs with microglia/macrophages. Unfortunately, this M2-like response is mostly negligible and transient compared to the durable pro-inflammatory (M1) polarization of microglia/macrophages after CNS damage.
The short M2 response dissipates within 3-7 days post-SCI, while M1 macrophages dominate the lesion site and the sorrounding tissue even at chronic phase. This is in contrast with the typical dynamics following cutaneous wound healing processes, where a welldefined shift in macrophage effector functions takes place. In this case the initial M1
phenotype ensures the sterility of the wound and induces apoptosis in neutrophils, this consequently causes the recruitment of M2 macrophages that promotes tissue healing and brings the inflammatory process to an end. A similar M1 to M2 macrophage shift does not occur after SCI, and chronic inflammation is indeed a hallmark of spinal contusion/compression pathology. Interfering with the microglia/macrophages polarization by shifting the M1 pro-inflammatory activation towards an M2 pro-healing phenotype is currently one of the most promising approaches to increase tissue remodelling after SCI injury (Cusimano et al., 2012) .
Neuronal functional plasticity
Upon acute ischemic damage, neurons in the ischemic core (the region of low perfusion in which cells have lost their membrane potential terminally) release excitatory neurotransmitters (e.g. glutamate) and intracellular solutes (e.g. potassium) that trigger waves of peri-infarcts depolarizations (PIDs) (Dreier, 2011) . PIDs propagate from the lesion core towards the surrounding ischemic penumbra (the region where intermediate perfusion prevails along with partially preserved energy metabolism). Every PID induces intermittent depolarizations of the neurons of the penumbra, increasing the request of metabolic substrates (e.g. oxygen and glucose) in a zone that has reduced viability by definition (Doyle et al., 2008) . Subsequent PIDs lead to progressive enhancement of cellular death because of energetic failure and ultimately cause the ischemic core to enlarge and match the whole penumbra (Dijkhuizen et al., 1999) .
At this early time point, the major compensatory mechanism that can limit the spreading of these waves of depolarization are dendritic and synaptic pruning of the ischemic, but still viable, neurons (Mattson, 2008) . These first synaptic rearrangements are very similar to those occurring during neurodevelopment to mediate excessive synapses elimination through the activation of the complement system and microglia (Rossini et al., 2003) . It is known from post-natal studies that complement proteins mediate microglia-dependent pruning of synapses within neuronal circuits. As such, C1q-deficient mice display abnormal neocortical excitatory synaptic connectivity, as well as enhanced epileptiform activity (Chu et al., 2010) . These evidences suggest a possible reactivation of developmental pathways also in adult CNS disorders . After ischemic injury, complement proteins NSC-14-308_R1 8 become profoundly upregulated within the lesion (Pedersen et al., 2004) and, together with microglia (Hasbani et al., 2001) , mediate the first synaptic remodelling aimed at protecting vulnerable penumbral neurons from excessive excitotoxicity (Perry and O'Connor, 2010; Stephan et al., 2012) . It has also been shown that both C3a and C5a are neuroprotective against glutamate analogs by modulating the caspase cascade and the expression of glutamate receptor subunit 2 (GluR2) in vitro and in vivo (Mukherjee et al., 2008) . ischemic stroke in vivo is yet to be fully elucidated, and the complexity of experimental animal studies suggests that complement activation could be a "dual edged sword" exerting beneficial or detrimental effects depending on its timing and context (Brennan et al., 2012) .
After the initial synaptic depletion of dendritic arborizations, spine turnover undergoes a profound secondary up-regulation that is paralleled by an increase in axonal regeneration.
This period of increased plasticity (also referred to as critical period) is the preferential target of current rehabilitative therapies, and is mainly characterized by the preponderant expression of pro-plasticity (over growth-inhibitory) genes (Carmichael, 2006) . During this limited period, the transitory expression of growth-promoting molecules (e.g. small proline rich protein-1, myristoylated alanine-rich C-kinase substrate and growth associated protein-GAP-43) is coupled by a reduction of CSPGs (in the form of peri-neuronal nets) that eventually increase the final sprouting response (Carmichael et al., 2005) . Axonal fibre tracts and dendrites start to reorganize along the infarct rim, and regenerative mechanisms, even in distant part of the brain (e.g. the contralateral side) are enhanced. Fully differentiated neurons engage a neuronal growth program, elaborate a growth cone, extend an axon (or an axon collateral) and re-innervate unmatched targets via axonal sprouting. Interestingly, therapeutic approaches aimed at increasing perilesional tissue remodelling and contralesional plasticity (e.g. erythropoietin and VEGF administration) have shown to be extremely efficacious in promoting functional neurological recovery in the ischemic brain (Reitmeir et al., 2011; Reitmeir et al., 2012) .
The role of immune cells (either of the innate and adaptive immunity) in modulating axonal sprouting and regrowth has been extensively studied in mouse models of SCI. Growthpromoting molecules secreted by innate immune cells stimulate the intrinsic growth machinery of neurons to overcome surrounding inhibitory environment (Silver and Miller, 2004) . MCs attach to growing neurites (Furuno et al., 2005) where they can synthesize, store and release NGF, thus enhancing axonal sprouting of neuronal networks (Wilhelm et al., 2005) . Similarly, eosinophils synthesize specific neurotrophins, including NGF, brain-derived neurotrophic factor (BDNF) and neurotrophin (NT)-3, that can be released upon stimulation and have major stimulatory effect on neurite outgrowth (Foster et al., 2011 
Reparative regeneration
Precursor cells of the main neurogenic zones within the adult brain, as well as local progenitors, have a main role in the recovery after CNS injury in mice (Butti et al., 2012) .
Classically, two fundamental brain regions, i.e. the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampus, are responsible for neurogenesis in adult mammals (Doetsch, 2003) . Upon ischemic injury, neurogenesis in these areas is rapidly increased and a pool of progenitors is continuously generated up to four months after damage (Thored et al., 2006) . Although the extent of this proliferation is massive, the overall neurogenic response after stroke is insufficient in terms of (a) survival of immature or mature neurons and (b) their mobilization from the neurogenic niches.
The survival rate of adult NSC in the ischemic brain is very poor and about 80% of the newly-generated striatal neurons die during the first two weeks after their formation (Arvidsson et al., 2002) . , 2006) . While a local secretion of BDNF by resident microglia can be also induced by the production of IL-4 from T helper-2 polarized T cells (Ziv and Schwartz, 2008) , CD8 + T cells seem to have opposite effects on neurogenesis mediated by the release of granzyme B (Wang et al., 2010) .
Besides its role in modulating NSC survival, the immune system is a key player in the mobilization of newly formed neuroblasts from the neurogenic niches to the sites of damage.
NSC of the main murine neurogenic brain regions express both C3a and C5a receptors, and blockade of C3a signalling with a non-specific C3a receptor antagonist has been shown to attenuate basal and ischemia-induced neurogenesis in the adult mouse brain (Rahpeymai et al., 2006) . The effects of C3a on basal neurogenesis are mediated in synergy with stromal cell-derived factor-1α (SDF-1α) to promote neural progenitor cell migration and differentiation ). Interestingly, SDF-1α is strongly upregulated in the perilesional area after stroke, and behaves as an inflammatory stimulus that enhances progenitor proliferation and chain migration (Imitola et al., 2004) .
In the regenerating CNS, newly formed neurons and neuroblasts proliferate and migrate in chains towards the ischemic lesion along blood vessels, which provide an essential trophic support (Thored et al., 2007) . As a consequence of this interaction, neurogenesis and neovascularization after CNS damage show interdependent processes that share common mediators and signals (Snapyan et al., 2009) . Neovascularization in rodent models of cerebral ischemia comprises both angiogenesis (i.e. the out-growth of pre-existing vasculature) and vasculogenesis (i.e. the differentiation of endothelial progenitor cells into endothelial cells in situ). Both these mechanisms are rapidly induced upon brain stroke.
Gene expression analysis of mouse brains showed an increase of pro-angiogenic genes already at 1 hour post-ischemia, while endothelial cells around the infarcted brain area start to proliferate as early as 12-24 hours (Beck and Plate, 2009 ). Both angiogenesis and vasculogenesis lead to an increase of vessel density in the peri-infarcted region, which is visible at three days following the ischemic injury and results in vessel proliferation for more than 21 days following experimental cerebral ischemia.
Immune cells regulate the complex neovascularization in response to CNS damage in several ways. Infiltrating neutrophils are the first to be attracted towards the sites of deranged BBB where they contribute to further proteolysis of ECM proteins, thus increasing tissuebound VEGF in a positive loop that ultimately promotes focal angiogenesis (Lee, 2002) .
VEGF, the most important mitogen in the process of angiogenesis, is also secreted by infiltrating eosinophils and MCs (Horiuchi and Weller, 1997) . The occurrence of MCs on the vasculature wall, their location at the branch points of vessels, their production of proangiogenic factors (such as VEGF, FGF-2, TGF-β, TNF-α, IL-8, MMPs, tryptases and chymases), suggest indeed a prominent role for MCs in the neo-angiogenetic response after ischemic damage (Bennett et al., 2009; Sayed et al., 2011; Ribatti et al., 2000; 2011) . MCs further contribute to neo-vascularization after ischemia through the promotion of VEGF production from non-mast cell sources (e.g. via monocyte chemotactic protein-1 mediated recruitment of circulating macrophages) (Cohen et al., 1996) . Activated macrophage/microglial cells can in turn secrete TGF-β, Galectin-3 (Gal-3) and VEGF, finally enhancing the formation of new blood vessels within the ischemic region (Walther et al., 2000) . Interestingly, VEGF production by immune cells may be also important for successful brain remodelling after focal cerebral ischemia via mechanisms involving anti-inflammatory actions, thus suggesting a link between immunosuppressive and plasticity-promoting actions of VEGF (Herz et al., 2011) .
Although the role of dendritic cells (DCs) has raised great attention primarily in the context of T cell-mediated autoimmune diseases, recent evidences indicate that a profound activation of DCs is a common feature also after ischemic stroke. DCs positive for OX62 (a marker of rat lymph node-DCs) are present in the brains of rats subjected to permanent middle cerebral artery occlusion (MCAo) as early as one hour after ischemia, and keep accumulating up to six days post-injury (Kostulas et al., 2002) . DCs have been shown to be involved in the complex process of neovascularization, especially during the resolution of inflammation, when IL-10 might polarize DCs towards an alternative activated (AA-DCs)
phenotype (Riboldi et al., 2005) . The AA-DCs phenotype is characterized by an increased VEGF secretion, and it may contribute to neovascularization via a concomitant downregulation of the anti-angiogenic IL-12 (Penna and Adorini, 2000) . 
Conclusions
Damage to the central or peripheral nervous system results in the activation of complex immunological reactions that profoundly affect recovery after injury (Table 1) clearance through Ig-dependent macrophages activation (Bieber et al., 2001 ).
Many authors have also indicated that the lower regenerative potential of the CNS might be related to a prolonged duration of the immune activation after damage (Horner and Gage, 2000; Mescher and Neff, 2005) . The immune response in the CNS is indeed considerably more protracted compared to peripheral nerve injuries, and sustained meningeal inflammation (e.g. in the form of ectopic lymphoid-like structures) has been suggested to play a prominent detrimental role in many chronic CNS diseases (Aloisi and Pujol-Borrell, 2006) .
Shedding light on the mechanisms by which the sustained innate and adaptive immune activation interferes with CNS regeneration might lead to the identification of valuable targets for novel therapeutic treatments.
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Highlights:
• Early immune activation after acute CNS injury might have neuroprotective effects.
• Sustained inflammation profoundly shapes functional and structural plasticity within the CNS
• Modulation of the innate or adaptive immune responses represents a promising approach to treat acute CNS disorders.
